TQ Quiz | Navigating Glaucoma Management: Harnessing Vectors for Optimal Patient Care (Charleston 2025) by Events@optometricedu.com | Aug 6, 2025 | 2025 Charleston, TQ Courses | 0 comments "*" indicates required fields This field is hidden when viewing the formDate (Hidden) MM slash DD slash YYYY This field is hidden when viewing the formEvent Date (Hidden) MM slash DD slash YYYY This field is hidden when viewing the formEvent 90 days past date (Hidden) MM slash DD slash YYYY This field is hidden when viewing the formEvent Date Difference (Hidden)1. Anterior segment OCT is most useful to determine:* A - If the angle is open or closed B - The most posterior angle structure C - The presence of a Sampaolesi line D - The location of collector channels 2. Which of the following is a unique adverse effect of netarsudil?* A - Conjunctival hyperemia B - Corneal verticillata C - Reduction in pulse rate D - Increase in pupil diameter 3. Low vision consultation for patients with functional vision loss due to glaucoma is most effective:* A - Following bilateral loss of central fixation B - When constriction of visual field encroaches within 5 degrees of fixation C - Early in the course of disease D - When patients no longer meet visual requirements for driving 4. How do central corneal thickness values impact clinical management?* A - Thin central corneal thickness is a risk factor for development of glaucoma in patients with ocular hypertension B - Intraocular pressure measurements should be adjusted based on central corneal thickness measurements C - Central corneal thickness measurements are only valid if determine by ultrasound pachymetry D - Central corneal thickness measurements do not impact clinical management 5. What percentage of retinal ganglion cell axons are evaluated as the retinal nerve fiber layer on OCT?* A - 25% B - 50% C - 75% D - 100% 6. Which of the following visual field defects may be expected for a patient with a superior temporal notch in the neuroretinal rim?* A - Enlarged blind spot B - Inferior nasal step C - Superior arcuate scotoma D - No visual field defect is expected 7. Which class of IOP lowering medication has a teal-colored cap?* A - Beta blockers B - Alpha 2 adrenergic agonists C - Prostaglandin analogs D - Carbonic anhydrase inhibitors 8. Ideally, how many IOP readings should be gathered prior to making a treatment decision?* A - One B - Three C - As many as it takes until the IOP is greater than 21mmHg D - IOP is not relevant to therapeutic decision making in glaucoma 9. Maximally tolerated medical therapy is best described as:* A - One bottle of medication B - Two bottles of medication C - Three bottles of medication D - The maximum number of medications that an individual can tolerate 10. How does the 24-2C visual field test pattern differ from the 24-2 pattern?* A - There is a greater distance between test points in the 24-2C pattern B - There are an additional 10 paracentral test points in the 24-2C pattern C - The stimulus size is larger in the 24-2C pattern D - There is a wider area of the visual field tested in the 24-2C pattern 11. A patient states that they have multiple family members with glaucoma. Which family member’s glaucoma history is most relevant to the risk of your patient developing glaucoma?* A - A grandmother who uses latanoprost in both eyes B - A great uncle who has had a laser procedure for the treatment of glaucoma C - A brother-in-law with primary open angle glaucoma in both eyes with functional vision loss D - A sister who uses Rocklatan and Combigan in both eyes 12. How frequently should gonioscopy be clinically assessed?* A - Once, at the time of glaucoma diagnosis B - Every 8-10 years C - Every 1-2 years D - Every 3-6 months 13. Which of the following statements regarding primary open angle glaucoma is true?* A - It is a progressive, chronic optic neuropathy B - It is elevated intraocular pressure C - It is an uncommon cause of functional vision loss D - It is a condition characterized by the presence of angle recession 14. Diagnosis of primary angle closure suspect is correctly characterized by:* A - Inability to visualize posterior trabecular meshwork in at least 180 degrees without peripheral anterior synechiae and without elevated intraocular pressure B - No visualization of angle structures with intraocular pressure >27mmHg C - Ratio between the peripheral anterior chamber depth and corneal thickness of <1:1/2 using the Van Herick technique D - Trabecular-iris angle of <10 degrees measured on anterior chamber OCT 15. Which of the following statements regarding automated direct SLT is true?* A - It has demonstrated greater efficacy in clinical trials in comparison to standard SLT B - It is only approved for use in treatment-naïve eyes C - A contact lens is not required for the procedure D - There is an increased risk in post-procedure intraocular pressure spike in comparison to standard SLT 16. What is the intended purpose of the COAST trial?* A - To demonstrate that SLT is more effective than medical therapy in reducing IOP in eyes with open angle glaucoma B - To investigate the optimal energy level and frequency of laser therapy to treat glaucoma C - To evaluate the duration of effect of a single SLT procedure D - To assess the impact of SLT on quality of life in comparison to topical medical therapy 17. What is the mechanism of laser peripheral iridotomy (LPI) in the management of primary angle closure glaucoma?* A - To reverse or prevent pupil block B - To increase anterior chamber depth C - To prevent glaucomatous optic neuropathy D - To increase uveoscleral outflow 18. All of the following features are relevant to determining a target IOP, EXCEPT:* A - Age B - Disease severity C - Peak, untreated IOP D - Presence of dry eye disease 19. Benzodiazepine use is a relative contraindication for patients with which condition?* A - Primary open angle glaucoma B - Glaucomatocyclitic crisis C - Primary angle closure D - Pigmentary glaucoma 20. Long term use of topical ocular medications with benzalkonium chloride (BAK) may cause which of the following?* A - Decreased goblet cell density B - Increased intraocular pressure C - Cystoid macular edema D - Corneal verticillata Personal InformationName* First Last Email* Phone*OE Tracker #License #Address* Street Address Address Line 2 City State / Province / Region ZIP / Postal Code AfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCabo VerdeCambodiaCameroonCanadaCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos IslandsColombiaComorosCongoCongo, Democratic Republic of theCook IslandsCosta RicaCroatiaCubaCuraçaoCyprusCzechiaCôte d'IvoireDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatiniEthiopiaFalkland IslandsFaroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard Island and McDonald IslandsHoly SeeHondurasHong KongHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKorea, Democratic People's Republic ofKorea, Republic ofKuwaitKyrgyzstanLao People's Democratic RepublicLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacaoMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorth MacedoniaNorthern Mariana IslandsNorwayOmanPakistanPalauPalestine, State ofPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto RicoQatarRomaniaRussian FederationRwandaRéunionSaint BarthélemySaint Helena, Ascension and Tristan da CunhaSaint Kitts and NevisSaint LuciaSaint MartinSaint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint MaartenSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan MayenSwedenSwitzerlandSyria Arab RepublicTaiwanTajikistanTanzania, the United Republic ofThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkmenistanTurks and Caicos IslandsTuvaluTürkiyeUS Minor Outlying IslandsUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVenezuelaViet NamVirgin Islands, BritishVirgin Islands, U.S.Wallis and FutunaWestern SaharaYemenZambiaZimbabweÅland Islands Country Payment InformationPromotional CodeCharleston 2025 - Navigating Glaucoma Management: Harnessing Vectors for Optimal Patient Care*After 90 days, pricing will increase to $30. Price: Retake Discount Price: Promotional Discount Price: Credit Card* This field is hidden when viewing the formCourse Information (HIDDEN)This field is hidden when viewing the formCourse Name (HIDDEN)This field is hidden when viewing the formRetake Code (HIDDEN)This field is hidden when viewing the formQuiz URL (HIDDEN)Do not include ending backslash (aka no .com/)This field is hidden when viewing the formCE Hours Submit a Comment Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website
